No Data
No Data
Broker Revenue Forecasts For 2seventy Bio, Inc. (NASDAQ:TSVT) Are Surging Higher
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO).Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2
2seventy Bio Completes $40m Haemophilia A Program Deal With Novo Nordisk
Express News | Wedbush Reiterates Neutral on 2seventy Bio, Maintains $5 Price Target
2seventy bio (TSVT.US) rose nearly 4% in pre-market trading! Its type A hemophilia project was acquired by Novo Nordisk A/S (NVO.US).
Zhītōng Cáijīng APP learned that 2seventy bio (TSVT.US) has announced the completion of an assets purchase agreement. According to the agreement, Novo Nordisk (NVO.US) will acquire 2seventy bio's type A hemophilia project. In addition, Novo Nordisk will also acquire the rights to 2seventy bio's in-body gene editing technology. This technology is used for autologous or allogeneic cell therapy of immune cells for the treatment of autoimmune diseases. 2seventy bio also stated that the team currently involved in this project will join Novo Nordisk and...
Novo Nordisk Buys 2seventy Bio's Hemophilia A Program
No Data
JESSE JAMES8832 : quite a bit better than expected right?
JESSE JAMES8832 : 13.9m was the prediction
TrytosaveabitOP JESSE JAMES8832: I believe so yes?
TrytosaveabitOP JESSE JAMES8832: That rings a bell!
JESSE JAMES8832 : damn i thought this would do much better... short attack?
View more comments...